MedTech Acquisition filed a preliminary proxy outlining terms of its proposed merger with TriSalus Life Sciences. A shareholder meetign date has not been finalized.
The target is a privately held oncology therapeutics company integrating immunotherapy with disruptive delivery technology to transform the treatment paradigm for patients with liver and pancreatic tumors. TriSalus has raised about $170 million in venture funding from backers including Tullis Health Investors.
If approved, at closing the combined company expects to have at least $60 million in cash, which assumes “significant redemptions,” according to the press release announcing the deal two months ago. Cash at closing includes up to $50 million from a convertible note for which MedTech and TriSalus have entered into a non-binding term sheet with an institutional investor. Read more.
